RxDoctor Payments Data

John Mignone, MD

Advanced Heart Failure and Transplant Cardiology · Seattle, WANPI 1194834127

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Boehringer Ingelheim at 41.2% of the total. Reporting peaked in 2023 at $8,218 and has fallen 98.1% since, to $159 in 2025.

$18,581in general payments, 2019–2025

Across 79 payments — averaging $235.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$8K
  • Medtronic$7K
  • Abbott$1K
  • Lilly USA, LLC$1K
  • Impulse Dynamics (USA) Inc.$294
  • Abiomed$289
  • plus $738 from 9 others
$528,830in research payments, 2019–2025

Across 76 payments — averaging $6958.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$296K
  • Abbott$80K
  • Impulse Dynamics (USA) Inc.$63K
  • Medtronic$41K
  • Amgen$39K
  • American Regent$10K

What the payments were for

  • Consulting fees$4,00022%
  • Speaking & faculty fees$10,65057%
  • Travel & lodging$8334%
  • Food & beverage$3,09917%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim5$7,654
Medtronic(2 entities)16$7,080
Abbott38$1,475
Lilly USA, LLC2$1,050
Impulse Dynamics (USA) Inc.3$294
Abiomed5$289
Cvrx, Inc.2$262
Janssen Scientific Affairs, LLC1$153
Boston Scientific1$99
Edwards Lifesciences1$63
Catheter Precision Inc.1$50
Atricure, Inc.1$48
Novartis1$24
AbbVie1$23
Sensible Medical Innovations Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,581 in reported general payments places this provider in the 75th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

See all advanced heart failure and transplant cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$97,592
Medicare patients
581
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis61$1,546,413
EntrestoSacubitril/Valsartan72$106,376
EliquisApixaban36$54,126
JardianceEmpagliflozin56$52,843
FarxigaDapagliflozin Propanediol34$39,798
Metoprolol Succinate120$1,633
Rosuvastatin Calcium31$1,582
Losartan Potassium52$1,169
Carvedilol43$1,050
Candesartan Cilexetil18$1,023
Eplerenone16$828
Amlodipine Besylate14$777
Torsemide35$749
Bisoprolol Fumarate27$547
Spironolactone56$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24$106,37672 claims
Boehringer IngelheimJardiance$7,654$52,84356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

Other advanced heart failure and transplant cardiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →